For people with low-risk, early-stage cervical cancer, a simple hysterectomy removing the uterus and cervix has similar ...

UroGen Pharma ( NASDAQ: URGN) announced on Wednesday that the U.S. FDA has scheduled an Oncologic Drugs Advisory Committee ...

ImmunityBio's sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a ...

Shares of ImmunityBio touched a 52-week low after the company received a refusal-to-file letter from the Food and Drug Administration for a supplemental biologics license application for ...

CG Oncology Inc.’s latest research effort to treat bladder cancer is impressing investors.The Irvine-based biopharmaceutical ...

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...

Neal Shore, MD, FACS, discusses sasanlimab and its potential impact for community oncologists when treating patients with ...

May is Bladder Cancer Awareness Month and at Frontiers in Oncology, we are dedicated to spotlighting the groundbreaking discoveries transforming the ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

Clinical results offered at the recent meeting of the American Urological Association in Las Vegas signal that better treatments may lie ahead for non-muscle invasive bladder cancer.

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing ...